REGN - Spark Newswire

1 minute read

Regeneron Pharmaceuticals Sees Prelim U.S. Net Product Sales Of REGEN-COV Of ~$5.82B For FY21; Sees Prelim U.S. Net Product Sales Of EYLEA Injection Of ~$5.79B For FY21

Today, 4:21 PM

On January 10, 2022, at the virtual 40th Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc.

REGN

2 minute read

Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays

By Shanthi Rexaline

Today, 4:21 PM

An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE: PFE) shares from Neutral to Buy and increased the price target from $59 to $70.

PFE

1 minute read

Bernstein Upgrades Regeneron Pharmaceuticals to Outperform, Announces $660 Price Target

By Benzinga Newsdesk

Today, 4:21 PM

Bernstein analyst Aaron Gal upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Market Perform to Outperform and announces $660 price target.

REGN

3 minute read

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

By Shanthi Rexaline

Today, 4:21 PM

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.

ALNY

1 minute read

AstraZeneca’s COVID-19 Antibody Effective Against Omicron Variant

By Vandana Singh

Today, 4:21 PM

New preclinical data released by AstraZeneca Plc (NASDAQ:

AZN

3 minute read

Regeneron Early Monday Announced Phase 3 Dupixent Data In Children 6 Months To 5 Years For Moderate-To-Severe Atopic Dermatitis Showed Improvement In Skin Clearance, Reduced Disease Severity

By Benzinga Newsdesk

Today, 4:21 PM

Dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints Global regulatory filings planned in the coming months, starting

REGN

3 minute read

Events
News

Regeneron Announced New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma at ASH 2021

By Charles Gross

Today, 4:21 PM

egeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results for higher dose level cohorts of its investigational REGN5458 (BCMAxCD3) bispecific antibody, which were presented in an oral session at the 2021 American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

REGN